Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Veru Inc VERU

Healthcare Biotechnology
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VERU)

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

GlobeNewswire February 13, 2025

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

GlobeNewswire February 6, 2025

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswire February 4, 2025

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

GlobeNewswire January 27, 2025

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

GlobeNewswire December 31, 2024

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

GlobeNewswire November 26, 2024

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

GlobeNewswire November 5, 2024

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

GlobeNewswire October 21, 2024

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

GlobeNewswire October 16, 2024
View More News ››

Opinion & Analysis (NDAQ:VERU)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VERU)

Veru Reports Fiscal 2025 First Quarter Financial Results and

BREAKING NEWS: $VERU Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress--Company reported positive...
whytestocks - February 13, 2025

Veru to Present at the American Diabetes Association's 84th

NEWS: $VERU Veru to Present at the American Diabetes Association's 84th Scientific SessionsMIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE)...
whytestocks - June 10, 2024

Veru Reports Fiscal 2024 Second Quarter Financial Results an

News; $VERU Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical...
whytestocks - May 8, 2024

Veru Enrolls First Patients in Phase 2b Clinical Trial of En

BREAKING NEWS: $VERU Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality...
whytestocks - April 30, 2024

Veru to Present at the Oppenheimer 34th Annual Healthcare Li

NEWS: $VERU Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceMIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) ...
whytestocks - January 31, 2024

Oppenheimer has US$36 Target for VERU

Up Up and Away.  Poor Shorts. You almost have to feel sorry for them!
speedyg999 - July 11, 2022
View more Bullboard ››

Cascadia Minerals Ltd

Cascadia Minerals Ltd

Cascadia is a Canadian junior mining company focused on exploring for copper and gold in the Yukon and British Columbia ...
View More »